Venlafaxine Besylate ER (Venlafaxine Besylate) Patent Expiration, LOE Window & CMS Spending

Venlafaxine Besylate ER (Venlafaxine Besylate) by Almatica: FDA Orange Book LOE 2028-05-16, 9 AB generics, $1.2M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAlmatica
FDA Application & PathwayN215429 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2028-05-16
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors9
2024 CMS Total Public Spend$1.2M
2024 Medicare Part D Spend$759K
2024 Medicaid Spend$465K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel